StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Varivax (varicella live virus vaccine) by Quarter

Varivax (varicella live virus vaccine) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Varivax (varicella live virus vaccine): $260M in Q2 2026, up 8.3% from a year earlier.

Latest, Q2 2026
260
Period ended Jun 30, 2026
Change on a year earlier
+8.3%
240 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below

Where the Q2 2026 figure comes from

“|| Varivax | 260 | 240 | 8 | % | 8 | % | 495 | 489 | 1 | % | — | %”

Source: Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗

Reported in Form 10-Q / 10-K MD&A Pediatric Vaccines Disclosure (Q4 derived as Full Year − 9M).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVarivax (varicella live virus vaccine) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026260+8.3%Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗
Q1 2026Mar 31, 2026235-5.6%Form 10-Q (mrk-20260331.htm, filed 2026-05-04) ↗
Q4 2025Dec 31, 2025264-3.6%Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Q3 2025Sep 30, 2025288-4.3%Form 10-Q (mrk-20250930.htm, filed 2025-11-05) ↗
Q2 2025Jun 30, 2025240-9.8%Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗
Q1 2025Mar 31, 2025249-5.0%Form 10-Q (mrk-20260331.htm, filed 2026-05-04) ↗
Q4 2024Dec 31, 2024274+8.7%Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Q3 2024Sep 30, 2024301-7.4%Form 10-Q (mrk-20250930.htm, filed 2025-11-05) ↗
Q2 2024Jun 30, 2024266+4.3%Form 10-Q (mrk-20250630.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024262+11.0%Form 10-Q (mrk-20250331.htm, filed 2025-05-02) ↗
Q4 2023Dec 31, 2023252+2.9%Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Q3 2023Sep 30, 2023325+16.1%Form 10-Q (mrk-20240930.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 2023255-2.3%Form 10-Q (mrk-20240630.htm, filed 2024-08-05) ↗
Q1 2023Mar 31, 2023236+15.7%Form 10-Q (mrk-20240331.htm, filed 2024-05-03) ↗
Q4 2022Dec 31, 2022245+2.9%Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗
Q3 2022Sep 30, 2022280-3.4%Form 10-Q (mrk-20230930.htm, filed 2023-11-03) ↗

Breakdown

What makes up varivax (varicella live virus vaccine)

Cite this data

StockData. (2026). Merck Varivax (varicella live virus vaccine) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-varivax

See every metric in the Merck KPI table. Data updated Oct 26, 2026.